Piper Sandler reiterates Overweight on BridgeBio stock at $111 By Investing.com

Piper Sandler reiterated an Overweight rating on BridgeBio Pharma with a $111 price target, implying about 44% upside from the current $76.75 share price. The firm said BridgeBio is on track for regulatory filings for BBP-418, encaleret, and infigratinib, with combined peak sales potential of $4 billion annually, while analysts also expect continued sales growth. Litigation around Vyndamax remains a key overhang, but a near-term settlement could lift the shares by roughly 20% or more.

Analysis

BBIO is transitioning from a single-asset de-risking story into a multi-catalyst platform, which matters because the market is now willing to pay for pipeline optionality only if the lead asset keeps compounding. The key second-order effect is that every additional regulatory milestone reduces financing risk and widens the base of buyers that can underwrite the name on earnings power rather than pure event-driven biotech beta. That typically compresses the discount rate applied to the whole pipeline, not just the next filing.

The litigation overhang is the cleaner near-term trading catalyst because it can reprice the stock faster than regulatory progress. A settlement would likely be more powerful than a favorable trial outcome because it removes a binary discount and validates the franchise’s willingness to monetize durability; conversely, a protracted case keeps implied volatility elevated and may cap multiple expansion even if fundamentals continue to inflect. The practical implication is that BBIO can outperform on headlines, but sustained rerating needs a sequence of clean execution beats rather than one win.

The market may still be underestimating the durability of the revenue bridge if reimbursement dynamics protect share even in a later generic scenario. That lowers the probability of a cliff and shifts the debate from loss of the current asset to how much of the pipeline value is already in the stock. The contrarian risk is that consensus may be front-running multiple expansion too aggressively after a large run, leaving limited upside unless the company converts these catalysts into nearer-term cash flow visibility.

Key Decisions for Investors

• Stay long BBIO into the next 4-8 weeks only if sized as an event-driven position; expect the best risk/reward on litigation resolution or a clean regulatory filing, with upside skew from a settlement scenario and downside if timing slips.
• Use call spreads in BBIO rather than outright stock for the next catalyst window: upside can be captured if the name re-rates 15-25%, while premium outlay limits damage if the trial timeline drifts into late summer.
• If already long, hedge part of the position with short-dated puts ahead of litigation milestones; implied vol should stay elevated, making defined-risk protection relatively attractive versus selling the core equity.
• Consider a pair trade: long BBIO / short PFE over the next 3-6 months. The thesis is that BBIO’s multiple is being driven by de-risking and pipeline expansion, while PFE remains exposed to patent/portfolio overhangs and lacks comparable near-term upside convexity.
• Do not add aggressively on green headlines alone; wait for either a settlement confirmation or an FDA filing acceptance to re-underwrite the name, since the stock has likely pulled forward some of the optimistic scenario already.